

## Special Issue

# Metabolic Syndrome and NASH: From Molecular Basis to Therapy

### Message from the Guest Editors

The rising incidence of non-alcoholic fatty liver disease (NAFLD) globally goes hand in hand with the current epidemics of obesity. The relationship between body weight, fat accumulation and inflammation is probably the most relevant interaction within the constellation of metabolic syndrome leading to steatohepatitis (NASH), liver fibrosis, cirrhosis, cardiovascular complications and end-stage liver disease, namely, hepatocellular carcinoma. Therefore, much attention has been given to this special and complex link between body weight and the severity of NASH from the mechanistic and therapeutic perspectives, leading to a burgeoning and exciting field of research and drug development.

We invite investigators to contribute with either original research or review articles focusing on the variety of altered molecular mechanisms that link systemic inflammation, adipose tissue and liver fibrosis and their role in NASH and associated complications, as well as on the strategies for addressing the problem from a clinical and epidemiological perspective.

---

### Guest Editors

Dr. Juan Manuel Pericas

Dr. Andreea Ciudin

Dr. Francisco Javier Cubero

---

### Deadline for manuscript submissions

closed (30 November 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/89178](https://mdpi.com/si/89178)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).